Focused On-demand Library for Ribonuclease P protein subunit p21

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H633

UPID:

RPP21_HUMAN

Alternative names:

Ribonuclease P/MRP 21 kDa subunit; Ribonucleoprotein V

Alternative UPACC:

Q9H633; A2AAZ8; B0S834; B0S835; Q5JPL9; Q5JPM1; Q5STF8; Q5STF9; Q5STG2; Q5SU41; Q5SU42; Q86Y49; Q86Y50; Q86Y51; Q96F16

Background:

The Ribonuclease P protein subunit p21, also known as Ribonuclease P/MRP 21 kDa subunit or Ribonucleoprotein V, plays a crucial role in the generation of mature tRNA molecules. It achieves this by cleaving their 5'-ends as part of the ribonuclease P ribonucleoprotein complex. This process is vital for the proper functioning of cellular machinery and protein synthesis.

Therapeutic significance:

Understanding the role of Ribonuclease P protein subunit p21 could open doors to potential therapeutic strategies. Its critical function in tRNA processing highlights its importance in cellular biology and presents an opportunity for targeted drug discovery efforts.